REP-002

REP-002 is a **small-molecule drug candidate** reported by Repurpose.AI, later known as Model Medicines, as one of its internally discovered pipeline assets for **neurological disorders**. Publicly accessible information identifies it only at a high level as a patent-pending, Phase II/III-ready candidate discovered using the company's AI-enabled drug discovery and repurposing platform, but does **not** clearly disclose the underlying active ingredient, molecular target, mechanism of action, formulation, or precise indication. Because the identity and pharmacology of the asset are not publicly resolved in the available sources, REP-002 is best described as an investigational neurological-disorder program with limited disclosed technical detail.